Business Context and Reporting Period
This Form 8-K was filed by Shuttle Pharmaceuticals Holdings, Inc. on May 22, 2024. The filing serves as a Regulation FD disclosure to announce the Company's participation in the Lytham Partners Spring 2024 Investor Conference scheduled for May 30, 2024.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior period are reported in this document. The primary event is the scheduled investor presentation by CEO Dr. Anatoly Dritschilo.
Outlook, Management Commentary, and Risks
- Upcoming Presentation: CEO Dr. Anatoly Dritschilo will present updates on the Phase 2 Clinical Trial of Ropidoxuridine for the treatment of glioblastoma.
- Subsidiary Developments: The presentation will cover plans for Shuttle Diagnostics, Inc., specifically regarding predictive biomarkers for prostate cancer outcomes post-radiation and a novel PSMA ligand for theranostic applications.
- Forward-Looking Statements: The filing includes standard disclaimers that statements regarding future results, strategy, and clinical milestones are subject to risks and uncertainties that may cause actual results to differ materially.
Key Facts for Investor Verification
- Verify the date and access details for the Lytham Partners Spring 2024 Investor Conference (May 30, 2024).
- Confirm the specific clinical milestones and data to be presented regarding the Ropidoxuridine Phase 2 trial for glioblastoma.
- Review the attached Press Release (Exhibit 99.1) for detailed information on the Shuttle Diagnostics, Inc. pipeline.
- Note that this filing does not contain updated financial data; refer to the most recent Form 10-K or 10-Q for financial status.